IMTX
Price:
$9.35
Market Cap:
$1.02B
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carci...[Read more]
Industry
Biotechnology
IPO Date
2018-12-12
Stock Exchange
NASDAQ
Ticker
IMTX
According to Immatics N.V.’s latest financial reports and current stock price. The company's current ROE is -23.40%. This represents a change of 237.35% compared to the average of -6.94% of the last 4 quarters.
The mean historical ROE of Immatics N.V. over the last ten years is -43.76%. The current -23.40% ROE has changed -46.53% with respect to the historical average. Over the past ten years (40 quarters), IMTX's ROE was at its highest in in the March 2022 quarter at 73.85%. The ROE was at its lowest in in the September 2020 quarter at -145.58%.
Average
-43.76%
Median
-12.75%
Minimum
-395.05%
Maximum
302.14%
Discovering the peaks and valleys of Immatics N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 79.58%
Maximum Annual ROE = 302.14%
Minimum Annual Increase = -390.08%
Minimum Annual ROE = -395.05%
Year | ROE | Change |
---|---|---|
2023 | -43.09% | -344.86% |
2022 | 17.60% | -104.45% |
2021 | -395.05% | 79.58% |
2020 | -219.99% | -390.08% |
2019 | 75.84% | -74.90% |
The current ROE of Immatics N.V. (IMTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-140.18%
5-year avg
-112.94%
10-year avg
-43.76%
Immatics N.V.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than ALX Oncology Holdings Inc. (-946.88%), greater than BioAtla, Inc. (-169.69%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Replimune Group, Inc. (-52.15%), greater than Janux Therapeutics, Inc. (-8.78%), greater than Fennec Pharmaceuticals Inc. (-52.10%), greater than Edgewise Therapeutics, Inc. (-28.01%), less than Harmony Biosciences Holdings, Inc. (23.16%), less than Inhibrx Biosciences, Inc. (0%), less than Merus N.V. (1.62%), greater than Lyell Immunopharma, Inc. (-45.38%), greater than Kronos Bio, Inc. (-33.35%), greater than null (-68.82%),
Company | ROE | Market cap |
---|---|---|
-62.63% | $5.12B | |
-946.88% | $78.48M | |
-169.69% | $96.67M | |
-83.65% | $78.52M | |
-44.73% | $2.25B | |
-57.42% | $1.61B | |
-42.61% | $671.31M | |
-52.15% | $821.22M | |
-8.78% | $2.91B | |
-52.10% | $127.22M | |
-28.01% | $3.23B | |
23.16% | $1.88B | |
0% | $225.10M | |
1.62% | $3.51B | |
-45.38% | $325.12M | |
-33.35% | $57.28M | |
-68.82% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immatics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immatics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Immatics N.V.'s ROE?
How is the ROE calculated for Immatics N.V. (IMTX)?
What is the highest ROE for Immatics N.V. (IMTX)?
What is the 3-year average ROE for Immatics N.V. (IMTX)?
What is the 5-year average ROE for Immatics N.V. (IMTX)?
How does the current ROE for Immatics N.V. (IMTX) compare to its historical average?